title: Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
abstract: Adeno-associated virus (AAV) vectors are increasingly popular in gene therapy because they are unassociated with human disease, replication dependent, and less immunogenic than other viral vectors and can infect a variety of cell types. These vectors have been used in over 130 clinical trials, and one AAV product has been approved for treatment of lipoprotein lipase deficiency in Europe. To meet the demand for the increasing quantities of AAV required for clinical trials and treatment, a scalable high-capacity technology is required. Bioreactors meet these requirements but limited options are available for adherent HEK 293T/17 cells. Here we optimize the transient transfection of HEK293T/17 cells for the production of AAV human factor IX in a disposable fixed-bed bioreactor, the iCELLis(®) Nano (PALL Corporation). A fixed bed in the center of the iCELLis bioreactor is surrounded by culture medium that is pumped through the bed from the bottom of the bioreactor so that a thin film of the medium overflows the bed and is replenished with oxygen and depleted of CO2 as it returns to the surrounding medium reservoir. We show that this fixed-bed bioreactor can support as many as 2.5 × 10(8) cells/ml of fixed bed (1.9 × 10(6) cells/cm(2)). By optimizing culture and transfection parameters such as the concentration of DNA for transfection, day of harvest, size of PEI/DNA particles, and transfection medium, and adding an additional medium change to the process, we increased our yield to as high as 9.0 × 10(14) viral particles per square meter of fixed bed. We also show an average GFP transfection of 97% of cells throughout the fixed bed. These yields make the iCELLis a promising scalable technology for the clinical production of AAV gene therapy products.
authors.affiliation: Department of Therapeutics Production & Quality, St. Jude Children's Research Hospital , Memphis, Tennessee.
authors.forename: Alicia D
authors.initials: AD
authors.lastname: Powers
authors.affiliation: Department of Therapeutics Production & Quality, St. Jude Children's Research Hospital , Memphis, Tennessee.
authors.forename: Bryan A
authors.initials: BA
authors.lastname: Piras
authors.affiliation: Department of Therapeutics Production & Quality, St. Jude Children's Research Hospital , Memphis, Tennessee.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Clark
authors.affiliation: Department of Therapeutics Production & Quality, St. Jude Children's Research Hospital , Memphis, Tennessee.
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Lockey
authors.affiliation: Department of Therapeutics Production & Quality, St. Jude Children's Research Hospital , Memphis, Tennessee.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Meagher
mesh_terms: D019149:Bioreactors; D000229:Dependovirus / Q000235:genetics; D005164:Factor IX / Q000096:biosynthesis* / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000627:therapeutic use*; D057809:HEK293 Cells; D006801:Humans; D014162:Transfection
chemical_list: D005164:Factor IX